2018 PRESS RELEASES

Keyword Search
 
2018 | 2017 | 2016 | 2015
12/13/18
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
12/06/18
Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome
11/15/18
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018
11/09/18
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results
11/07/18
Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference
10/15/18
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
09/28/18
Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
09/28/18
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting
09/25/18
Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference
09/07/18
Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference
08/08/18
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results
07/23/18
Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
06/25/18
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
06/20/18
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
06/18/18
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
06/18/18
Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
06/14/18
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
06/01/18
Rhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
05/14/18
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results
05/09/18
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
05/09/18
Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
04/02/18
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
03/19/18
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
03/12/18
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
03/07/18
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
01/04/18
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity